About Viela Bio
Viela Bio is a Healthcare company based in Gaithersburg (United States) founded in 2017, and was acquired by Horizon Therapeutics in December 2020. Viela Bio has raised $357.25 million across 2 funding rounds from investors including Goldman Sachs, Astrazeneca and Horizon Therapeutics. The company has 170 employees. Its focus areas include Life Sciences, Immunology, Drugs and Diversified. Its legal entity is VIELA BIO, INC. Its competitors include Moderna, BridgeBio and BeiGene; 3 of its 3 listed competitors have raised funding.
Company details
Developer of biologics for treating severe inflammation and autoimmune diseases. Their lead candidate inebilizumab, which is indicated for Neuromyelitis Optica Spectrum Disorder. Other candidates include HZN-825 for diffuse cutaneous systemic sclerosis, HZN-4920 for Sjögrens syndrome, rheumatoid arthritis, kidney transplant, and others. It is a humanized monoclonal antibody that binds and depletes CD19 B cells including plasmablasts and plasma cells.
- Headquarters Gaithersburg, United States
- Employees 170
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website vielabio.com
- Social LinkedIn
- Acquired by Horizon Therapeutics (Dec 2020)
- Legal Name Viela Bio, Inc.
- Annual Revenue$11.65 M (USD)-77as on Dec 31, 2020
- Net Profit-$150.67 M (USD)-74as on Dec 31, 2020
- EBITDA-$153.88 M (USD)-72as on Dec 31, 2020
- Total Equity Funding$357.25M (USD)
in 2 rounds
- Latest Funding Round$75M (USD), Series B
Jun 2019
- InvestorsGoldman Sachs
& 11 more
- Employee Count170
- Acquired byHorizon Therapeutics
(Dec 2020)
Funding Insights of Viela Bio
Viela Bio has successfully raised a total of $357.25M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $75 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $357.25M
- Total Rounds 2
- Last Round Series B — $75M
- First Round $282.25M
(Feb 2018)
- Investors Count 11
All 2 funding rounds of Viela Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2019 | $75M | Series B | – | HBM Healthcare Investments | |
| Feb 2018 | $282.25M | Series A | – | 6 Dimensions Capital, Boyu Capital |
12 investors in total: 12 institutional.
Investors in Viela Bio
Viela Bio has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Goldman Sachs, Astrazeneca and Horizon Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
Private equity investments in China are managed by TMCP. | terramagnumcap.com | Chaoyang, China | ||
Investment banking services are delivered across multiple financial sectors. | 1869 | goldmansachs.com | New York, United States | |
An investment platform is provided for diverse sectors and geographies. | 1974 | temasek.com.sg | Singapore, Singapore | |
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
Life-Sciences focused early and growth stage VC firm funding companies in China & the US | 6dimensionscapital.com | Pudong, China | ||
Boyu Capital is recognized as a leading alternative asset management firm. | boyucapital.com | Hong Kong, China | ||
Global private equity investments are managed with long-term focus. | hillhouseinvestment.com | New York, United States | ||
Healthcare innovation is supported through venture capital investments. | sironacap.com | |||
| cormorant-asset.com |
Investor details for Viela Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Viela Bio
1108 people are tracked at Viela Bio (431 in leadership, 47 in board & advisors, 630 in team); the tracked headcount is 170.
| Name | Role | Group |
|---|---|---|
Seamus Lyons | Sr. Director Manufacturing | Leadership |
Alma Holden | Associate Director Validation | Leadership |
Francisco J Aguado-Rodriguez | Director Of Quality - Data Integrity And Ops Management Review GPO | Leadership |
Vivian Tu | Senior Director, Competitive Intelligence | Leadership |
Amro Essmat | Director , Quality - Regional Quality Head TMEA - Turkey, Middle East & Africa At Amgen | Leadership |
Miriam O'Sullivan | Executive Director Plant Manager | Leadership |
Mara Wachholder | Director, Treasury | Leadership |
Thiago Pastore | Human Resources Director, Brazil | Leadership |
Chris Pacheco | Director Manufacturing | Leadership |
Aditya Tulsyan | Associate Director Data Sciences, Operations | Leadership |
Andreas Reichelt | Senior Director Contract Manufacturing | Leadership |
Laura Cooke | Program Management Executive Director | Enterprise Transformation | Leadership |
Ned Endler | Executive Director US Trade, Channel Strategy And Execution | Leadership |
Amy Belisle | Associate Director Quality | Leadership |
Susie Tappouni | Head of Corporate Affairs | Leadership |
Kim Worrell | Associate Director HR Systems & Solutions | Leadership |
Jessica Vargas | Director, HR Business Partner | Leadership |
Mark Corder | Senior Director | Leadership |
Tara U. | Director, Global Corporate Affairs, Operations | Leadership |
Elena Pakhomov | Executive Director Of Sales | Leadership |
1088 more people are available in the full profile.
Complete people profiles for Viela Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Viela Bio
5 dated milestones of Viela Bio across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Viela Bio is founded.
- Funding First funding round of $282.3M.
- Funding Latest funding round, Series B, of $75.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Horizon Therapeutics.
Competitors of Viela Bio
Viela Bio has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and BeiGene.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. |
Detailed competitors of Viela Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Viela Bio (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Viela Bio
Complete news archive for Viela Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Viela Bio
Viela Bio was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Viela Bio is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Viela Bio is a funded company, having raised a total of $357.25M across 2 funding rounds to date. The company's 1st funding round was a Series A of $282.25M, raised on Feb 2018.
Viela Bio has 170 employees.
Annual revenue of Viela Bio is $11.65M as on Dec 31, 2020.
Developer of biologics for treating severe inflammation and autoimmune diseases. Their lead candidate inebilizumab, which is indicated for Neuromyelitis Optica Spectrum Disorder. Other candidates include HZN-825 for diffuse cutaneous systemic sclerosis, HZN-4920 for Sjögrens syndrome, rheumatoid arthritis, kidney transplant, and others. It is a humanized monoclonal antibody that binds and depletes CD19 B cells including plasmablasts and plasma cells.
Viela Bio has 12 investors. Key investors include Goldman Sachs, Astrazeneca, Horizon Therapeutics, Temasek, and HBM Healthcare Investments.
Viela Bio operates through Viela Bio, Inc..
Yes. Viela Bio was acquired by Horizon Therapeutics in December 2020.